Therapeutic strategies for Huntington's disease

Purpose of review Huntington's disease is a fatal autosomal dominant neurodegenerative disorder caused by a trinucleotide expansion in theHTTgene, and current therapies focus on symptomatic treatment. This review explores therapeutic approaches that directly target the pathogenic mutation, disruptHTTmRNA or its translation. Recent findings Zinc-finger transcription repressors and CRISPR-Cas9 therapies targetHTTDNA, thereby preventing all downstream pathogenic mechanisms. These therapies, together with RNA interference (RNAi), require intraparenchymal delivery to the brain in viral vectors, with only a single delivery potentially required, though they may carry the risk of irreversible side-effects. Along with RNAi, antisense oligonucleotides (ASOs) target mRNA, but are delivered periodically and intrathecally. ASOs have safely decreased mutant huntingtin protein (mHTT) levels in the central nervous system of patients, and a phase 3 clinical trial is currently underway. Finally, orally available small molecules, acting on splicing or posttranslational modification, have recently been shown to decrease mHTT in animal models. Huntingtin-lowering approaches act upstream of pathogenic mechanisms and therefore have a higha priorilikelihood of modifying disease course. ASOs are already in late-stage clinical development, whereas other strategies are progressing rapidly toward human studies.